Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AL-3789 Sterile · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AL-3789 | EXPERIMENTAL | AL-3789 Sterile Suspension, single depot administration of 0.8 mL in the study eye |
| No treatment | NO_INTERVENTION | Fellow eye, as randomized |
| Name | Type | Description |
|---|---|---|
| AL-3789 Sterile Suspension | DRUG | Single administration by anterior juxtascleral depot |
Inclusion Criteria: * Diagnosis of open-angle glaucoma and treated for at least 30 days prior to Screening Visit with a topical prostaglandin analog as monotherapy. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Pregnant, intend to become pregnant, breastfeeding. * D...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
AL-3789 Sterile is an investigational small molecule being developed for the treatment of open-angle glaucoma. It is administered as a sterile ophthalmic formulation. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
AL-3789 Sterile is being developed by Alcon Inc. (NYSE: ALC). Alcon is a pharmaceutical company focused on eye care, and this drug candidate is part of its ophthalmology pipeline for glaucoma treatment.
AL-3789 Sterile is in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval. The Phase 2 trial has been completed, and the drug remains under evaluation for the treatment of open-angle glaucoma.
AL-3789 Sterile has one completed Phase 2 clinical trial, identified as NCT00643669, titled "24 Hour IOP Lowering Efficacy of AL-3789." The trial enrolled 25 participants with open-angle glaucoma in the United States and evaluated the drug's effect on intraocular pressure over 24 hours.
No alternative names for AL-3789 Sterile have been disclosed. The drug is identified solely by this designation in its clinical development program. It is a distinct investigational candidate being studied for open-angle glaucoma.